UF scientists to work with German firm in prostate cancer treatment research

University of Florida department of urology officials and CureVac, a German-based biopharmaceutical company, signed a collaboration agreement June 17 to advance research in prostate cancer vaccine therapy at a signing ceremony at the UF Cancer & Genetics Research Complex. From left, Peter Pevonka, senior associate dean for research affairs at the UF College of Medicine, Dr. Thomas Lander, managing director and chief medical officer of CureVac, Dr. Johannes Vieweg, professor and chairman and Wayne and Marti Huizenga eminent scholar of the department of urology at the UF College of Medicine, and Dr. Michael Good, interim dean of the UF College of Medicine. (Sarah Kiewel/University of Florida)